GU Cancers 2024 | Sacituzumab govitecan and other ADCs in prostate cancer

Umang Swami, MD, MS, University of Utah, Salt Lake City, UT, comments on the various antibody-drug conjugates (ADCs) being investigated for prostate cancer, including sacituzumab govitecan. The ADC consists of a trop-2-directed antibody linked to SN-38, the payload. Dr Swami additionally highlights nectin-4-directed antibodies in clinical trials. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.